Odevixibat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and CHUIKYO (Japan), among others, recommended or restricted odevixibat, while DMC (Denmark) and NYE METODER (Norway) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.”, while PBAC (Australia) recorded not recommended for “Progressive familial intrahepatic cholestasis (PFIC)”.
Assessment has run over 5.1 years, from 18 Jun 2021 at AWMSG (Wales) to 2026 at PBAC (Australia).
TLV (Sweden) changed its position: not recommended on 24 Apr 2023, recommended by 25 Nov 2025, after a resubmission.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 18 of 24 records date from 2023 or later.
3 distinct indication wordings are recorded for odevixibat by the agencies that label one in English (AWMSG, PBAC and SMC).
5 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess odevixibat, on 18 Jun 2021; SMC (Scotland) did not open a file until 8 Jun 2026 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 6 years in total.
6 of the 13 agencies here assessed odevixibat more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
odevixibat has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for odevixibat reads 11 recommended, 8 not recommended, 2 deferred and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Alagille syndrome (ALGS) | Not Recommended | source |
| SMC (Scotland) | 8 Jun 2026 | Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. | accepted | source |
| CIPM (Spain) | 25 Mar 2026 | Indicaciones terapéuticas autorizadas: KAYFANDA está indicado para el tratamiento del prurito colestásico en pacientes c… | not financed by the SNS · art. 92 c, d | source |
| AOTMIT (Poland) | 3 Dec 2025 | programu lekowego B.175 „Leczenie chorych z zespołem Alagille’a (ICD-10: Q44.7) | recommended conditionally | source |
| TLV (Sweden) | 25 Nov 2025 | Bylvay ingår i högkostnadsskyddet | general subsidy | source |
19 further decisions for odevixibat, across 11 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 15 further source documents.
Related molecules
- maralixibat — same ATC class A05A — Bile and liver therapy
- elafibranor — same ATC class A05A — Bile and liver therapy
- ursodeoxycholic acid — same ATC class A05A — Bile and liver therapy
- obeticholic acid — same ATC class A05A — Bile and liver therapy
- osimertinib — also decided by SMC in 2026Q2
- brentuximab — also decided by SMC in 2026Q2
Coverage: 24 decisions for odevixibat from 13 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class A05A — Bile and liver therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.